Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Non-Infectious Anterior Uveitis Clear all
Completed Phase 4 Interventional Results available

Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients

NCT02764697
View directory record Official record
Conditions
Uveitis, Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, Scleritis, Clinically Significant Macular Edema
Interventions
H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
Drug
Lead sponsor
Tampa Bay Uveitis Center, LLC
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis

NCT01505088
View directory record Official record
Conditions
Anterior Uveitis
Interventions
40 mg/mL Dexamethasone phosphate ophthalmic solution, Prednisolone Acetate (1%) Eyedrops, 100 mM sodium citrate buffer solution, Placebo Eyedrops
Drug
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 85 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
39
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 2 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis

NCT02255032
View directory record Official record
Conditions
Uveitis, Macular Edema, Uveitis, Posterior, Uveitis, Anterior, Panuveitis, Uveitis, Intermediate
Interventions
4 mg CLS-TA, 0.8 mg CLS-TA
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2021 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 3 Interventional Results available

Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis

NCT02595398
View directory record Official record
Conditions
Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
Interventions
4mg CLS-TA Suprachoriodal Injection, Sham Procedure
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Jul 22, 2026, 2:48 PM EDT
Recruiting Phase 3 Interventional

The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment

NCT05486468
View directory record Official record
Conditions
Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate
Interventions
Yutiq 0.18 MG Drug Implant, Sham Injection
Drug · Other
Lead sponsor
Texas Retina Associates
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 2 Interventional

A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis

NCT05523765
View directory record Official record
Conditions
Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Non-infectious Pan Uveitis
Interventions
Brepocitinib
Drug
Lead sponsor
Priovant Therapeutics, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • Pasadena, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 3 Interventional Results available

SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.

NCT03131154
View directory record Official record
Conditions
Non-infectious Anterior Uveitis
Interventions
ADX-102 Ophthalmic Solution (0.5%), Vehicle of ADX-102 Ophthalmic Solution
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Prescott, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Jul 22, 2026, 2:48 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study

NCT06085079
View directory record Official record
Conditions
Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
Interventions
Ixekizumab Prefilled Syringe
Drug
Lead sponsor
Massachusetts Eye Research and Surgery Institution
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 3 Interventional

A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis

NCT00404742
View directory record Official record
Conditions
Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
Interventions
Placebo, LX211
Drug
Lead sponsor
Lux Biosciences, Inc.
Industry
Eligibility
13 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 3 Interventional

A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis

NCT00404885
View directory record Official record
Conditions
Uveitis, Anterior, Panuveitis
Interventions
Placebo, LX211
Drug
Lead sponsor
Lux Biosciences, Inc.
Industry
Eligibility
13 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
14
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 3 Interventional Results available

Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis

NCT03097315
View directory record Official record
Conditions
Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
Interventions
4 mg CLS-TA Suprachoriodal Injection
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Phoenix, Arizona • Beverly Hills, California • Mountain View, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis

NCT04222712
View directory record Official record
Conditions
Non-infectious Anterior Uveitis
Interventions
TRS01 eye drops
Drug
Lead sponsor
Tarsier Pharma
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Palisades Park, New Jersey • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis

NCT02406209
View directory record Official record
Conditions
Non-infectious Anterior Uveitis
Interventions
NS2, Prednisolone acetate ophthalmic suspension (1%)
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Lancaster, California • Golden, Colorado • Hamden, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2023 · Synced Jul 22, 2026, 2:48 PM EDT
Completed No phase listed Observational Results available

MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301

NCT02952001
View directory record Official record
Conditions
Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
Interventions
4 mg CLS-TA Suprachoriodal Injection, Sham procedure
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Phoenix, Arizona • Mountain View, California • Fort Lauderdale, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 3 Interventional

A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis

NCT00404612
View directory record Official record
Conditions
Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
Interventions
Placebo, LX211
Drug
Lead sponsor
Lux Biosciences, Inc.
Industry
Eligibility
13 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis

NCT02309385
View directory record Official record
Conditions
Non-Infectious Anterior Uveitis
Interventions
8% Dexamethasone Sodium Phosphate - Visulex, 15% Dexamethasone Sodium Phosphate - Visulex, Prednisolone Acetate (1%) Eye Drops
Drug
Lead sponsor
Aciont Inc
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Cambridge, Massachusetts • Charlotte, North Carolina • Fargo, North Dakota + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis

NCT00694135
View directory record Official record
Conditions
Uveitis, Anterior
Interventions
EGP-437 1.6 mA-min at 0.4 with EyeGate® II System, EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System, EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System, EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System
Drug
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
13
States / cities
Miami, Florida • Atlanta, Georgia • Boston, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2010 · Synced Jul 22, 2026, 2:48 PM EDT
Terminated Phase 2Phase 3 Interventional

A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis

NCT00333996
View directory record Official record
Conditions
Anterior Uveitis
Interventions
Dexamethasone
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2011 · Synced Jul 22, 2026, 2:48 PM EDT
Recruiting Phase 2 Interventional

Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis

NCT07285070
View directory record Official record
Conditions
Non-infectious Anterior Uveitis
Interventions
Tacrolimus ophthalmic solution
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
5
States / cities
Miami, Florida • Waltham, Massachusetts • Palisades Park, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 22, 2026, 2:48 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

NCT06431373
View directory record Official record
Conditions
Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Interventions
Brepocitinib PO QD, Placebo PO QD
Drug
Lead sponsor
Priovant Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
53
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 3 Interventional Results available

A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma

NCT05042609
View directory record Official record
Conditions
Non-infectious Anterior Uveitis, Uveitic Glaucoma
Interventions
TRS01, FDA approved steroid eye drop (masked)
Drug
Lead sponsor
Tarsier Pharma
Industry
Eligibility
0 Years to 75 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
19
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 2 Interventional

A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior Uveitis

NCT04706741
View directory record Official record
Conditions
Uveitis
Interventions
Izokibep, Prednisone/Prednisolone
Drug
Lead sponsor
ACELYRIN Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
4
States / cities
Los Angeles, California • Palo Alto, California • Hagerstown, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2024 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis

NCT02517619
View directory record Official record
Conditions
Anterior Uveitis
Interventions
Dexamethasone Phosphate Ophthalmic Solution, Prednisolone Acetate Ophthalmic (1%)
Drug
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 85 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of AIN457 in Noninfectious Uveitis

NCT00685399
View directory record Official record
Conditions
Non-infectious Uveitis
Interventions
AIN457, AIN 457
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
20
States / cities
Beverly Hills, California • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2017 · Synced Jul 22, 2026, 2:48 PM EDT